OA12232A - Pharmaceutical compositions of glycogen phosporylase inhibitors. - Google Patents
Pharmaceutical compositions of glycogen phosporylase inhibitors. Download PDFInfo
- Publication number
- OA12232A OA12232A OA1200200290A OA1200200290A OA12232A OA 12232 A OA12232 A OA 12232A OA 1200200290 A OA1200200290 A OA 1200200290A OA 1200200290 A OA1200200290 A OA 1200200290A OA 12232 A OA12232 A OA 12232A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- composition
- hydroxy
- strand
- mono
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18994200P | 2000-03-16 | 2000-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12232A true OA12232A (en) | 2006-05-10 |
Family
ID=22699402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200290A OA12232A (en) | 2000-03-16 | 2001-03-16 | Pharmaceutical compositions of glycogen phosporylase inhibitors. |
Country Status (32)
Country | Link |
---|---|
US (1) | US20010053778A1 (et) |
EP (1) | EP1263414A1 (et) |
JP (1) | JP2003526654A (et) |
KR (1) | KR20020081445A (et) |
CN (1) | CN1418089A (et) |
AP (1) | AP2002002621A0 (et) |
AR (1) | AR027656A1 (et) |
AU (1) | AU2001242669A1 (et) |
BG (1) | BG107037A (et) |
BR (1) | BR0109189A (et) |
CA (1) | CA2403241A1 (et) |
CO (1) | CO5280087A1 (et) |
CZ (1) | CZ20022955A3 (et) |
EA (1) | EA200200858A1 (et) |
EE (1) | EE200200530A (et) |
HU (1) | HUP0204583A2 (et) |
IL (1) | IL151320A0 (et) |
IS (1) | IS6508A (et) |
MA (1) | MA26882A1 (et) |
MX (1) | MXPA02009097A (et) |
NO (1) | NO20024386L (et) |
OA (1) | OA12232A (et) |
PA (1) | PA8513601A1 (et) |
PE (1) | PE20011184A1 (et) |
PL (1) | PL360780A1 (et) |
SK (1) | SK12622002A3 (et) |
SV (1) | SV2002000343A (et) |
TN (1) | TNSN01040A1 (et) |
TR (1) | TR200202184T2 (et) |
WO (1) | WO2001068055A1 (et) |
YU (1) | YU67202A (et) |
ZA (1) | ZA200207290B (et) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0016555A (pt) * | 1999-12-23 | 2002-09-17 | Pfizer Prod Inc | Composições farmacêuticas que proporcionam concentrações acrescidas de droga |
CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
EA006777B1 (ru) | 2001-06-22 | 2006-04-28 | Пфайзер Продактс Инк. | Фармацевтические композиции адсорбатов аморфного лекарственного средства |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
PT1404300E (pt) | 2001-06-22 | 2009-11-09 | Bend Res Inc | Composições farmacêuticas de dispersões de fármacos e polímeros neutros |
BR0307344A (pt) | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
JP4865989B2 (ja) | 2002-02-01 | 2012-02-01 | ベンド・リサーチ・インコーポレーテッド | 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法 |
BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
ATE540671T1 (de) * | 2003-08-04 | 2012-01-15 | Bend Res Inc | Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
WO2005065657A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
ES2353309T3 (es) | 2004-03-08 | 2011-03-01 | Prosidion Ltd. | Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa. |
US20090298745A1 (en) * | 2004-12-02 | 2009-12-03 | Gerard Hugh Thomas | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors |
DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
BR112015002056A2 (pt) | 2012-08-24 | 2017-07-04 | Dow Global Technologies Llc | éter de celulose esterificado, composição, dispersão sólida, processo para produzir a dispersão sólida, forma de dosagem e invólucro de cápsula |
HUE057701T2 (hu) | 2012-09-11 | 2022-05-28 | Medivation Prostate Therapeutics Llc | Enzalutamid kiszerelési formái |
AU2014290333B2 (en) | 2013-07-19 | 2018-11-08 | Siga Technologies, Inc. | Amorphous Tecovirimat preparation |
CN103709171B (zh) * | 2014-01-20 | 2015-09-16 | 武汉大学 | 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法 |
CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
US11291701B1 (en) * | 2021-02-04 | 2022-04-05 | Seed Edibles | Orally disintegrating, sublingual and buccal formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
PT832066E (pt) * | 1995-06-06 | 2001-12-28 | Pfizer | N-substituido-(indole-2-carbonil)-amidas e derivados como inibidores de glicogenio-fosforilase |
ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
-
2001
- 2001-03-14 US US09/805,828 patent/US20010053778A1/en not_active Abandoned
- 2001-03-14 PE PE2001000246A patent/PE20011184A1/es not_active Application Discontinuation
- 2001-03-14 AR ARP010101185A patent/AR027656A1/es not_active Application Discontinuation
- 2001-03-15 TN TNTNSN01040A patent/TNSN01040A1/fr unknown
- 2001-03-15 SV SV2001000343A patent/SV2002000343A/es not_active Application Discontinuation
- 2001-03-16 EA EA200200858A patent/EA200200858A1/ru unknown
- 2001-03-16 HU HU0204583A patent/HUP0204583A2/hu unknown
- 2001-03-16 KR KR1020027012009A patent/KR20020081445A/ko not_active Application Discontinuation
- 2001-03-16 PL PL36078001A patent/PL360780A1/xx not_active Application Discontinuation
- 2001-03-16 MX MXPA02009097A patent/MXPA02009097A/es unknown
- 2001-03-16 BR BR0109189-1A patent/BR0109189A/pt not_active Application Discontinuation
- 2001-03-16 JP JP2001566619A patent/JP2003526654A/ja active Pending
- 2001-03-16 IL IL15132001A patent/IL151320A0/xx unknown
- 2001-03-16 TR TR2002/02184T patent/TR200202184T2/xx unknown
- 2001-03-16 SK SK1262-2002A patent/SK12622002A3/sk unknown
- 2001-03-16 WO PCT/IB2001/000394 patent/WO2001068055A1/en not_active Application Discontinuation
- 2001-03-16 CA CA002403241A patent/CA2403241A1/en not_active Abandoned
- 2001-03-16 EE EEP200200530A patent/EE200200530A/et unknown
- 2001-03-16 AU AU2001242669A patent/AU2001242669A1/en not_active Abandoned
- 2001-03-16 EP EP01915586A patent/EP1263414A1/en not_active Withdrawn
- 2001-03-16 AP APAP/P/2002/002621A patent/AP2002002621A0/en unknown
- 2001-03-16 CN CN01806619A patent/CN1418089A/zh active Pending
- 2001-03-16 YU YU67202A patent/YU67202A/sh unknown
- 2001-03-16 CZ CZ20022955A patent/CZ20022955A3/cs unknown
- 2001-03-16 CO CO01021769A patent/CO5280087A1/es not_active Application Discontinuation
- 2001-03-16 OA OA1200200290A patent/OA12232A/en unknown
- 2001-03-16 PA PA20018513601A patent/PA8513601A1/es unknown
-
2002
- 2002-08-16 IS IS6508A patent/IS6508A/is unknown
- 2002-08-26 BG BG107037A patent/BG107037A/bg unknown
- 2002-09-11 ZA ZA200207290A patent/ZA200207290B/xx unknown
- 2002-09-11 MA MA26810A patent/MA26882A1/fr unknown
- 2002-09-13 NO NO20024386A patent/NO20024386L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1418089A (zh) | 2003-05-14 |
CA2403241A1 (en) | 2001-09-20 |
CO5280087A1 (es) | 2003-05-30 |
HUP0204583A2 (hu) | 2003-04-28 |
ZA200207290B (en) | 2003-09-11 |
BG107037A (bg) | 2003-04-30 |
NO20024386D0 (no) | 2002-09-13 |
AU2001242669A1 (en) | 2001-09-24 |
IS6508A (is) | 2002-08-16 |
CZ20022955A3 (cs) | 2003-09-17 |
MA26882A1 (fr) | 2004-12-20 |
MXPA02009097A (es) | 2003-03-12 |
AP2002002621A0 (en) | 2002-09-30 |
NO20024386L (no) | 2002-11-13 |
JP2003526654A (ja) | 2003-09-09 |
US20010053778A1 (en) | 2001-12-20 |
EE200200530A (et) | 2004-04-15 |
YU67202A (sh) | 2006-01-16 |
PA8513601A1 (es) | 2004-08-31 |
PL360780A1 (en) | 2004-09-20 |
EP1263414A1 (en) | 2002-12-11 |
SV2002000343A (es) | 2002-07-03 |
AR027656A1 (es) | 2003-04-09 |
IL151320A0 (en) | 2003-04-10 |
EA200200858A1 (ru) | 2003-02-27 |
SK12622002A3 (sk) | 2004-02-03 |
KR20020081445A (ko) | 2002-10-26 |
WO2001068055A1 (en) | 2001-09-20 |
BR0109189A (pt) | 2003-05-27 |
TNSN01040A1 (fr) | 2005-11-10 |
PE20011184A1 (es) | 2001-11-15 |
TR200202184T2 (tr) | 2003-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12232A (en) | Pharmaceutical compositions of glycogen phosporylase inhibitors. | |
JP6932746B2 (ja) | エンザルタミドの製剤 | |
JP6577980B2 (ja) | アピキサバン製剤 | |
TWI635863B (zh) | 帕博西里之固態劑型 | |
ES2205000T5 (es) | Composición farmacéutica que contiene irbesartán | |
AU2005324132B2 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
JP4780522B2 (ja) | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 | |
JP6530845B2 (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法 | |
EP1793824A1 (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
US20100062070A1 (en) | Pulverzed crystals of olmesartan medoxomil | |
ES2366394T3 (es) | Composiciones de eprosartán. | |
PT2165702E (pt) | Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida | |
CN109963565B (zh) | 一种药物组合物及其制备方法 | |
WO2007102038A1 (en) | Ziprasidone formulations | |
US20240216347A1 (en) | Bezuclastinib formulations | |
TW202410894A (zh) | Glp1醫藥組合物 | |
Neha | Key words: Crospovidone; Sodium starch glycolate; Pregelatinised starch; Potato starch; Avicel pH 101. Journal of Pharmaceutical Research Vol. 11, No. 4, December 2012: 142-149. ENHANCEMENT OF DISSOLUTION OF TELMISARTAN BY SURFACE SOLID DISPERSION TECHNIQUE Sood Neha, Khatry Sadhna* and Arora Sandeep Chitkara College of Pharmacy, Chitkara University, Rajpura-140401, Patiala (Punjab), India. Received on: 28.08. 2012 Revised: 16.10. 12 Accepted: 01.11. 12* Correspondence: sadhna_khatry@ yahoo. com, sadhna. khatry@ chitkara. edu. in | |
CN104436155A (zh) | 含有左旋氨氯地平与培哚普利的药物组合物及制备方法 |